Mixed Results Eyed for Generics’ Attacks on Shire ADHD Franchise
Wall Street analysts predict Actavis’ ANDA on attention-deficit hyperactivity disorder (ADHD) drug Intuniv won’t infringe Shire’s patents, and the generic-drug maker could launch as soon as October if it wins approval.
300 N. Washington St., Suite 200, Falls Church, VA 22046, USA.
Phone (703) 538-7600 - Fax (703) 538-7676 - Toll free (888) 838-5578.
Copyright by FDAnews. All rights reserved. Do not duplicate or redistribute in any form.